Literature DB >> 7785761

Isotopomer study of lipogenesis in human hepatoma cells in culture: contribution of carbon and hydrogen atoms from glucose.

W N Lee1, L O Byerley, S Bassilian, H O Ajie, I Clark, J Edmond, E A Bergner.   

Abstract

Recent developments in the application of stable isotopes and mass spectrometry have permitted the estimation of precursor enrichment and fractional synthesis of the product through mass isotopomer analysis. Thus, the application of isotopomer analysis in studies with 2H- and 13C-labeled glucose may potentially overcome the limitations of traditional methods which can only estimate the fractional use of carbon and hydrogen from glucose for lipogenesis. To illustrate this approach, isotope incorporation and mass isotopomer distribution were determined in fatty acids and cholesterol from a hepatoma cell line (Hep G2) grown in media containing specific (C1 or C6) 2H- or 13C-labeled glucose. Using the binomial model, the respective precursor enrichment, and fractional synthesis of palmitate, stearate and cholesterol were determined using mass isotopomer distribution analysis. In 1 week, 80% of palmitate, 65.5% of stearate, and 50% of cholesterol molecules in the cell extract were derived from de novo synthesis. Under serum-free condition, glucose contributed about 80% of the carbon of the newly synthesized lipids. Using the relative isotope yield of [1-13C] and [6-13C]glucose and a standard formula, the contribution of the pentose pathway to glucose catabolism was calculated to be 4.7%. Fractional syntheses of palmitate, stearate, and cholesterol determined using [1-2H]glucose agreed well with values determined using 13C-labeled glucose. After correcting for the contribution of deuterium label from the glycolytic pathway, the deuterium from [1-2H]glucose contributed 4.7% of the total reducing equivalents for lipogenesis. Unlike radioisotope studies, the stable isotope approach provides information from the perspective of the product and insight into the economy of acetyl units and reducing equivalents which were otherwise not available.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7785761     DOI: 10.1006/abio.1995.1197

Source DB:  PubMed          Journal:  Anal Biochem        ISSN: 0003-2697            Impact factor:   3.365


  5 in total

Review 1.  Role of abnormal lipid metabolism in development, progression, diagnosis and therapy of pancreatic cancer.

Authors:  Julian Swierczynski; Areta Hebanowska; Tomasz Sledzinski
Journal:  World J Gastroenterol       Date:  2014-03-07       Impact factor: 5.742

2.  Novel quantitative insights into carbon sources for synthesis of poly hydroxybutyrate in Synechocystis PCC 6803.

Authors:  Vaishali Dutt; Shireesh Srivastava
Journal:  Photosynth Res       Date:  2017-11-09       Impact factor: 3.573

3.  Characterizing phenotype with tracer based metabolomics.

Authors:  Wai Nang P Lee
Journal:  Metabolomics       Date:  2006-05-20       Impact factor: 4.290

4.  Metabolic sensitivity of pancreatic tumour cell apoptosis to glycogen phosphorylase inhibitor treatment.

Authors:  W-N P Lee; P Guo; S Lim; S Bassilian; S T Lee; J Boren; M Cascante; V L W Go; L G Boros
Journal:  Br J Cancer       Date:  2004-12-13       Impact factor: 7.640

5.  Impact of the solvent capacity constraint on E. coli metabolism.

Authors:  Alexei Vazquez; Qasim K Beg; Marcio A Demenezes; Jason Ernst; Ziv Bar-Joseph; Albert-László Barabási; László G Boros; Zoltán N Oltvai
Journal:  BMC Syst Biol       Date:  2008-01-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.